Publicaciones en colaboración con investigadores/as de Hospital Clínico San Carlos de Madrid (147)

2024

  1. Correction: Update on the management of elderly patients with colorectal cancer (Clinical and Translational Oncology, (2023), 26, 1, (69-84), 10.1007/s12094-023-03243-0)

    Clinical and Translational Oncology

  2. Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence

    Future Oncology, Vol. 20, Núm. 20, pp. 1401-1413

  3. SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023)

    Clinical and Translational Oncology, Vol. 26, Núm. 11, pp. 2800-2811

  4. Update on the management of elderly patients with colorectal cancer

    Clinical and Translational Oncology, Vol. 26, Núm. 1, pp. 69-84

2022

  1. A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)

    European Journal of Cancer, Vol. 177, pp. 154-163

  2. Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancer

    Cancer Biomarkers, Vol. 34, Núm. 2, pp. 201-210

  3. Correction to: SEOM‑GEMCAD‑TTD clinical guidelines for localized rectal cancer (2021) (Clinical and Translational Oncology, (2022), 24, 4, (646-657), 10.1007/s12094-022-02816-9)

    Clinical and Translational Oncology

  4. Molecular Classification of Colorectal Cancer by microRNA Profiling: Correlation with the Consensus Molecular Subtypes (CMS) and Validation of miR-30b Targets

    Cancers, Vol. 14, Núm. 21

  5. SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021)

    Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 646-657

2021

  1. Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study

    ESMO open, Vol. 6, Núm. 2, pp. 100062

  2. Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS)

    Health and Quality of Life Outcomes, Vol. 19, Núm. 1

2020

  1. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected

    Clinical Colorectal Cancer, Vol. 19, Núm. 3, pp. e110-e116

  2. FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: The randomised phase III VISNÚ-1 trial

    ESMO Open, Vol. 5, Núm. 6

  3. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study

    The Lancet Gastroenterology and Hepatology, Vol. 5, Núm. 3, pp. 285-294

  4. SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019)

    Clinical and Translational Oncology, Vol. 22, Núm. 2, pp. 236-244

  5. The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls

    Expert Opinion on Biological Therapy, Vol. 20, Núm. 1, pp. 15-22

2019

  1. Management and supportive treatment of frail patients with metastatic pancreatic cancer

    Journal of Geriatric Oncology, Vol. 10, Núm. 3, pp. 398-404

  2. Phase I/II trial to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with pancreatic cancer and an ECOG performance status of 2

    Journal of Clinical Oncology

  3. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018)

    Clinical and Translational Oncology, Vol. 21, Núm. 1, pp. 46-54

  4. Treatment and outcome of patients with stage is testicular cancer: A retrospective study from the Spanish germ cell cancer group

    Journal of Urology, Vol. 202, Núm. 4, pp. 742-747